PT1119349E - Antagonistas de receptor de factor de crescimento epidérmico para tratamento de hipersecreção de muco nos pulmões - Google Patents

Antagonistas de receptor de factor de crescimento epidérmico para tratamento de hipersecreção de muco nos pulmões Download PDF

Info

Publication number
PT1119349E
PT1119349E PT99943729T PT99943729T PT1119349E PT 1119349 E PT1119349 E PT 1119349E PT 99943729 T PT99943729 T PT 99943729T PT 99943729 T PT99943729 T PT 99943729T PT 1119349 E PT1119349 E PT 1119349E
Authority
PT
Portugal
Prior art keywords
mucus
lungs
growth factor
receptor antagonists
factor receptor
Prior art date
Application number
PT99943729T
Other languages
English (en)
Inventor
Jay A Nadel
Kiyoshi Takeyama
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT1119349E publication Critical patent/PT1119349E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99943729T 1998-08-18 1999-08-17 Antagonistas de receptor de factor de crescimento epidérmico para tratamento de hipersecreção de muco nos pulmões PT1119349E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9702398P 1998-08-18 1998-08-18

Publications (1)

Publication Number Publication Date
PT1119349E true PT1119349E (pt) 2008-10-14

Family

ID=22260380

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99943729T PT1119349E (pt) 1998-08-18 1999-08-17 Antagonistas de receptor de factor de crescimento epidérmico para tratamento de hipersecreção de muco nos pulmões

Country Status (36)

Country Link
US (6) US6270747B1 (pt)
EP (2) EP1119349B1 (pt)
JP (2) JP2002539072A (pt)
KR (1) KR100609646B1 (pt)
CN (1) CN1184961C (pt)
AR (1) AR020220A1 (pt)
AT (1) ATE399541T1 (pt)
AU (1) AU760766B2 (pt)
BR (1) BR9912672A (pt)
CA (1) CA2337422C (pt)
CO (1) CO5130028A1 (pt)
CY (1) CY1110370T1 (pt)
CZ (1) CZ2001584A3 (pt)
DE (1) DE69939022D1 (pt)
DK (1) DK1119349T3 (pt)
EA (1) EA004316B1 (pt)
EE (1) EE200100097A (pt)
ES (1) ES2310047T3 (pt)
HK (1) HK1036219A1 (pt)
HR (1) HRP20010119B1 (pt)
HU (1) HUP0103894A3 (pt)
ID (1) ID27345A (pt)
IL (2) IL140855A0 (pt)
MY (1) MY126490A (pt)
NO (1) NO327000B1 (pt)
NZ (1) NZ509271A (pt)
PH (2) PH12010000215A1 (pt)
PL (1) PL200940B1 (pt)
PT (1) PT1119349E (pt)
RS (1) RS50273B (pt)
SI (1) SI1119349T1 (pt)
SK (1) SK287805B6 (pt)
TR (1) TR200100560T2 (pt)
TW (1) TWI250019B (pt)
UA (1) UA73722C2 (pt)
WO (1) WO2000010588A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
RS50273B (sr) 1998-08-18 2009-07-15 The Regents Of The Univeristy Of California, Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20030236300A1 (en) * 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003221767B2 (en) * 2002-04-24 2008-07-31 Research Development Foundation Synergistic effects of nuclear transcription factor NF-kB inhibitors and anti-neoplastic agents
JP2005535626A (ja) * 2002-06-24 2005-11-24 リサーチ　ディベロップメント　ファンデーション クルクミンによるヒト多発性骨髄腫の治療
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20060241130A1 (en) * 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
US7195899B1 (en) * 2003-03-14 2007-03-27 Florida State University Research Foundation, Inc. Cell-based biosensor for harmful airborne agents
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US7462646B2 (en) 2003-08-26 2008-12-09 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
WO2005105765A1 (en) * 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
US7915223B2 (en) * 2004-09-27 2011-03-29 Technion Research & Development Foundation Ltd. Antimicrobial agents
JP2008514586A (ja) * 2004-09-27 2008-05-08 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 新規な抗菌剤
JP4690158B2 (ja) * 2004-09-28 2011-06-01 スギ生物科学研究所株式会社 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
WO2006035706A1 (ja) * 2004-09-28 2006-04-06 Dainippon Ink And Chemicals, Inc. 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
US20070082865A1 (en) * 2005-10-11 2007-04-12 Washington University Compositions and methods for treatment of airway hypersecretion
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) * 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2008124496A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
WO2008132737A1 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
EP2527008A3 (en) * 2007-04-30 2013-01-16 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
US8648191B2 (en) * 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
EP3513787A1 (en) * 2011-01-10 2019-07-24 Invion, Inc Use of beta-adrenergic inverse agonists for smoking cessation
MX366347B (es) 2012-08-03 2019-07-05 Cedars Sinai Medical Center Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
CN105939721A (zh) 2013-12-02 2016-09-14 塞尔巴有限公司 用于治疗皮肤疾病的草药组合
EP3328498B1 (en) 2015-07-29 2021-05-05 Sirbal Ltd. Medical kit comprising herbal combinations for treating psoriasis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932481A (en) * 1954-06-15 1960-04-12 Breer Bipod camera support
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
FR2502627A1 (fr) * 1981-02-02 1982-10-01 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1173549B (it) * 1984-04-02 1987-06-24 Corvi Camillo Spa Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4904786A (en) * 1986-01-27 1990-02-27 American Home Products Corporation Quinoline compounds as antiallergic and antiinflammatory agents
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
KR900701771A (ko) * 1988-09-28 1990-12-04 로버트 에이 아미테이지 리폭시게나아제 효소를 억제하는 1, 4-디히드로티오나프토퀴논 및 헤테로시클릭 협동 작용물
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5116616A (en) * 1991-04-29 1992-05-26 Bio-Technology General Corp. Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
DE4310051A1 (de) 1992-04-11 1993-10-14 Byk Gulden Lomberg Chem Fab Weitere Verwendung substituierter Pyridazine
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
CA2144314A1 (en) * 1992-09-11 1994-03-31 James M. Wilson Non-human animal with xenograft of on airway populated by human cells
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
WO1995006764A2 (en) 1993-09-03 1995-03-09 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
JP3436311B2 (ja) * 1993-09-13 2003-08-11 メルク フロスト カナダ アンド カンパニー 粘液分泌性上皮細胞の化生変化を測定する方法
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
WO1995023225A2 (en) 1994-02-23 1995-08-31 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US20030114379A1 (en) * 1994-03-08 2003-06-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP0824525B1 (en) 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
JP3370340B2 (ja) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
EP1037639A4 (en) 1997-12-19 2002-04-17 Smithkline Beecham Corp HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
EP1066286B1 (en) * 1998-03-04 2009-04-29 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
RS50273B (sr) 1998-08-18 2009-07-15 The Regents Of The Univeristy Of California, Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6972288B1 (en) 1999-02-27 2005-12-06 Boehringer Ingelheim Pharma Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
ES2234698T3 (es) * 1999-10-19 2005-07-01 MERCK & CO., INC. Inhibidores de tirosina quinasa.
MXPA02009855A (es) 2000-04-08 2003-03-27 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Also Published As

Publication number Publication date
HRP20010119A2 (en) 2002-02-28
AU5676699A (en) 2000-03-14
MY126490A (en) 2006-10-31
EA200100136A1 (ru) 2001-10-22
KR20010085412A (ko) 2001-09-07
US20010041178A1 (en) 2001-11-15
NZ509271A (en) 2003-10-31
IL140855A (en) 2011-02-28
PL351765A1 (en) 2003-06-16
EP1119349B1 (en) 2008-07-02
HK1036219A1 (en) 2001-12-28
SK2162001A3 (en) 2002-08-06
CA2337422A1 (en) 2000-03-02
US7358222B2 (en) 2008-04-15
AU760766B2 (en) 2003-05-22
IL140855A0 (en) 2002-02-10
KR100609646B1 (ko) 2006-08-04
HUP0103894A3 (en) 2003-07-28
CY1110370T1 (el) 2015-04-29
NO20010749D0 (no) 2001-02-14
WO2000010588A9 (en) 2000-08-10
ATE399541T1 (de) 2008-07-15
CZ2001584A3 (cs) 2002-06-12
SI1119349T1 (sl) 2008-12-31
WO2000010588A3 (en) 2001-05-25
AR020220A1 (es) 2002-05-02
CA2337422C (en) 2010-11-02
YU13201A (sh) 2005-07-19
US20030148990A1 (en) 2003-08-07
TWI250019B (en) 2006-03-01
US8048844B1 (en) 2011-11-01
EE200100097A (et) 2002-06-17
UA73722C2 (en) 2005-09-15
ID27345A (id) 2001-04-05
PL200940B1 (pl) 2009-02-27
DE69939022D1 (de) 2008-08-14
EP1119349A2 (en) 2001-08-01
WO2000010588A2 (en) 2000-03-02
CN1184961C (zh) 2005-01-19
HRP20010119B1 (en) 2008-05-31
EP1970058A1 (en) 2008-09-17
DK1119349T3 (da) 2008-10-13
TR200100560T2 (tr) 2002-05-21
JP2009221212A (ja) 2009-10-01
PH12010000215A1 (en) 2015-07-27
BR9912672A (pt) 2002-06-11
CN1354657A (zh) 2002-06-19
SK287805B6 (sk) 2011-10-04
NO327000B1 (no) 2009-03-30
US20080175797A1 (en) 2008-07-24
PH12010000216A1 (en) 2015-07-27
NO20010749L (no) 2001-04-17
ES2310047T3 (es) 2008-12-16
US6566324B2 (en) 2003-05-20
HUP0103894A2 (hu) 2002-04-29
EA004316B1 (ru) 2004-02-26
RS50273B (sr) 2009-07-15
CO5130028A1 (es) 2002-02-27
JP2002539072A (ja) 2002-11-19
US6551989B2 (en) 2003-04-22
US6270747B1 (en) 2001-08-07
US8071074B2 (en) 2011-12-06
US20010036919A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
PL351765A1 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
IL139030A0 (en) Therapeutic angiogenic factors and methods for their use
IL138864A0 (en) Methods and apparatus for scout-based cardiac calcification scoring
PL341596A1 (en) Pharmacological composition for treating concentration disorders and hyperkinesia
EP1200086A4 (en) THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
IL137413A0 (en) Methods and apparatus for calcification scoring
HUP9900163A2 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
PL348107A1 (en) Therapy for improving cognition
HUP9904109A3 (en) Local anesthetic for external use
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
HUP0104543A3 (en) Lime treatment
HUP0200738A2 (hu) Eljárás az inkontinencia kezelésére
GB9928837D0 (en) Novel bone cement
EP1234869A4 (en) CLEANING COMPOSITION AND METHOD FOR PRODUCING THE SAME
PL352479A1 (en) Application of hydrocortisone antagonists in treating cardiac insufficiencies
HUP0102772A3 (en) Novel compounds derived from alpha-d-xylose, preparation method and therapeutic use
GB9816897D0 (en) Therapeutic use
GB2347965B (en) Template and method for use thereof
GB9923117D0 (en) Insect-paper and methods for its formation and use
GB9824573D0 (en) Methods for stimulating bone formation
SI1117403T1 (en) Mglur5 antagonists for the treatment of pain and anxiety
TW382324U (en) Improvement for structure of facial tissue
TW356713U (en) Apparatus used for stopping the snore of sleeper
AU1591P (en) Lime Delight Philotheca myoporoides
PL331674A1 (en) Carpenter's wooden putty and apparatus for making same